Impaired Cytotoxic Activity of Interleukin 2 (IL 2)-cultured Large Granular Lymphocytes (LGL) in Childhood Acute Lymphoblastic Leukemia. Quantitative Measurement of IL 2 Receptor Expression of IL 2-cultured LGL

References

• Cantrell D. A., Smith K. A. The interleukin-2 T-cell system. A new cell growth model. Science 1984; 224: 1312–1316
   PubMed Web of Science ®Google Scholar
• Robb R. J. Interleukin 2. The molecule and its function. Immunol Today 1984; 5: 203–209
   PubMedGoogle Scholar
• Smith K. A. Interleukin-2. Inception, impact, and implications. 1988. Science 1988; 240: 1169–1176
   PubMed Web of Science ®Google Scholar
• Herberman R. B., Ortaldo J. R. Natural killer cells. Their role in defenses against disease. Science 1981; 214: 24–30
   PubMed Web of Science ®Google Scholar
• Lotzova E., Savary C. A., Herberman R. B. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 1987; 138: 2718–2727
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T., Seipp C. A., Simpson C. G., White D. E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• Timonen T., Ortaldo J. R., Herberman R. B. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J. Exp. Med 1981; 153: 569–582
   PubMed Web of Science ®Google Scholar
• Yamada S., Ortaldo J. R. Regulation of human large granular lymphocyte and T cell growth and function by recombinant interleukin 2. Acquisition of potent cytotoxic capabilities. J. Leuk. Biol 1987; 42: 263–272
   PubMed Web of Science ®Google Scholar
• Yamada S., Ruscetti F. W., Overton W. R., Herberman R. B., Birchenall-Sparks M. C., Ortaldo J. R. Regulation of human large granular lymphocyte and T cell growth and function by recombinant interleukin 2. Induction of interleukin 2 receptor and promotion of growth of cells with enhanced cytotoxicity. J. Leuk. Biol 1987; 41: 505–517
   PubMed Web of Science ®Google Scholar
• Aur R. J. A., Simone J. V., Verzosa M. S., Hustu H. O., Barker L. F., Pinkel D. P., Rivera G., Dahl G. V., Wood A., Stagner S., Mason C. Childhood acute lymphocytic leukemia. Study VIII. Cancer 1978; 42: 2123–2134
   PubMed Web of Science ®Google Scholar
• Frei III E., Sallan S. E. Acute lymphoblastic leukemia. Treatment. Cancer 1978; 42: 828–838
   PubMed Web of Science ®Google Scholar
• West W. H., Cannon G. B., Kay H. D., Bonnard G. D., Herberman R. B. Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line. Characterization of effector cells. J. Immunol 1977; 118: 355–361
   PubMed Web of Science ®Google Scholar
• Fox D. A., Hussey R. E., Fitgerald K. A., Besnsussan A., Daley J. F., Schlossman S. F., Reinherz E. L. Activation of human thymocytes via the 50kd T11 sheep erythrocyte binding protein induces the expression of interleukin 2 receptors on both T3+ and T− populations. J. Immunol 1985; 134: 330–335
   PubMed Web of Science ®Google Scholar
• Oonishi T., Uyesaka N. A new standard fluorescence microsphere for quantitative flow cytometry. J Immunol Methods 1985; 84: 143–154
   PubMed Web of Science ®Google Scholar
• Robb R. J., Greene W. C., Rusk C. M. Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. J Exp. Med 1984; 160: 1126–1146
   PubMed Web of Science ®Google Scholar
• Yamada S., Miyagawa Y., Komiyama A., Akabane T. Analysis on natural killer cell defects in childhood acute lymphoblastic leukemia. Jpn. J. Clin. Oncol 1984; 14: 75–80
   PubMed Web of Science ®Google Scholar
• Yamada S., Miyagawa Y. Komiyama. A. Decreased cytotoxic potential of fresh and recombinant interleukin 2-cultured large granular lymphocytes in childhood acute lymphoblastic leukemia. Leukemia Res 1991; 15: 367–372
   PubMed Web of Science ®Google Scholar
• McGeorge M. B., Russell E. C., Mohanakumar T. Immunologic evaluation of long-term effects of childhood ALL chemotherapy. Analysis of in vitro NK- and K-cell activities of peripheral blood lymphocytes. Am. J. Hematol 1982; 12: 19–27
   PubMed Web of Science ®Google Scholar
• Herberman R. B., Hiserodt J., Vujanovic N., Balch C., Lotzova E., Bolhuis R., Golub S., Lanier L. L., Phillips J. H., Riccardi C., Ritz J., Santoni A., Schmidt R. E., Uchida A. Lymphokine-activated killer cell activity. Characteristics of effector cells and their progenitors in blood and spleen. Immunol. Today 1987; 6: 178–181
   Google Scholar
• Adler A., Albo V., Blatt J., Whiteside T. L., Herbermann R. B. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. II. Feasibility of LAK generation in children with active disease and in remission. Blood 1989; 74: 1690–1697
   PubMed Web of Science ®Google Scholar
• Ridgway D., Borzy M. S. Elevated production of interleukin-2 by lymphocytes from children with acute leukemia. J. Pediatr 1989; 114: 384–391
   PubMed Web of Science ®Google Scholar
• Borzy M. S., Ridgway D. Prolonged defects of interleukin-2 production, responsiveness, and receptor expression in patients with acute lymphoblastic leukemia. Blood 1989; 73: 1608–1614
   PubMed Web of Science ®Google Scholar
• Uchiyama T., Broder S., Waldmann T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac(+) cells. J. Immunol 1981; 126: 1393–1397
   PubMed Web of Science ®Google Scholar
• Waldmann T. A., Goldman C. K., Robb R. J., Depper J. M., Leonard W. J., Sharrow S. O., Bongiovanni K. F., Korsmeyer S. J., Greene W. C. Expression of interleukin 2 receptors on activated human B cells. J. Exp. Med 1984; 160: 1450–1466
   PubMed Web of Science ®Google Scholar
• Tsudo M., Goldman C. K., Bongiovanni K. F., Chan W. C., Winton E. F., Yagita M., Grimm E. A., Waldmann T. A. The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc. Natl. Acad. Sci. U.S.A 1987; 84: 5394–5398
   PubMed Web of Science ®Google Scholar
• Phillips J. H., Takeshita T., Sugamura K., Lanier L. L. Activation of natural killer cells via the p75 interleukin 2 receptor. J. Exp. Med 1989; 170: 291–295
   PubMed Web of Science ®Google Scholar
• Robertson M. J., Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421–2438
   PubMed Web of Science ®Google Scholar
• Fujii M., Sugamura K., Sano K., Nakai M., Sugita K., Hinuma Y. High-affinity receptor-mediated internalization and degradation of interleukin 2 in human T cells. J. Exp. Med 1986; 163: 550–562
   PubMed Web of Science ®Google Scholar
• Robb R. J., Greene W. C. Internalization of interleukin 2 is mediated by the β chain of the high-affinity interleukin 2 receptor. J. Exp. Med 1987; 165: 1201–1206
   PubMed Web of Science ®Google Scholar
• Le thi Bich-Thuy, Dukovich M., Peffer N. J., Fauci A. S., Kehrl J. H., Greene W. C. Direct activation of human resting T cells by IL 2. The role of an IL 2 receptor distinct from the Tac protein. J. Immunol 1987; 139: 1550–1556
   PubMed Web of Science ®Google Scholar
• Kehrl J. H., Dukovich M., Whalen G., Katz P., Fauci A. S., Greene W. C. Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells. J. Clin. Invest 1988; 81: 200–205
   PubMed Web of Science ®Google Scholar
• Blue M. L., Daley J. F., Levine H., Craig K. A., Schlossman S. F. Identification and isolation of a T4+T8+ cell with high T3 expression in human thymus. A possible late intermediate in thymocyte differentiation. J. Immunol 1987; 139: 1065–1069
   PubMed Web of Science ®Google Scholar
• Caligiuri M. A., Zmuidzinas A., Manley T. J., Levine H., Smith K. A., Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer subset with high affinity receptors. J. Exp. Med 1990; 171: 1509–1526
   PubMed Web of Science ®Google Scholar
• Nagler A., Lanier L. L., Phillips J. H. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J. Exp. Med 1990; 171: 1527–1533
   PubMed Web of Science ®Google Scholar
• Voss S. D., Robb R. J., Weil-Hillman G., Hank J. A., Sugamura K., Tsudo M., Sondel P. M. Increased expression of the interleukin 2(IL-2) receptor β chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy. p70 expression does not alone predict the level of intermediate affinity IL-2 binding. J. Exp. Med 1990; 172: 1101–1114
   PubMed Web of Science ®Google Scholar
• Einspahr K. J., Abraham R. T., Dick C. J., Leibson P. J. Protein tyrosine phosphorylation and p56lck modification in IL-2 or phorbol ester-activated human natural killer cells. J. Immunol 1990; 145: 1490–1497
   PubMed Web of Science ®Google Scholar
• Moingeon P., Stebbins C. C., D'Adamio L., Lucich J., Reinherz E. L. Human natural killer cells and mature T lymphocytes express identical CD3 subunits as defined by cDNA cloning and sequence analysis. Eur. J. Immunol 1990; 20: 1741–1745
   PubMed Web of Science ®Google Scholar